-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On August 9, 2021, Rongchang Biotech reached a cooperation agreement with Seagen, another overseas ADC leader company.
Seagen obtained the global rights and interests of Rongchang Biologics HER2 ADC vedicitumumab, and Rongchang Biotech retained the Asian region (except Singapore and Japan).
Clinical development and commercialization rights
.
According to the agreement, Seagen will pay Rongchang Biological an advance payment of US$200 million, a milestone amount of US$2.
With the successive success of HER2 ADC drug DS-8201 and Trop2 ADC drug Trodelvy, ADC has set off a new round of research and development and trading boom
.
Since 2019, overseas multinational pharmaceutical companies have entered ADC: In 2020, Gilead, MSD, and BI will each make large acquisitions of ADC pharmaceutical companies.
The world’s most popular ADC drug targets under research are HER2, Trop2, CD19, etc.
The new ADC drug targets traded include ROR1, LIV-1, TF, etc.
; in addition, ADC technology-related transactions are relatively hot, and representative companies include LegoChem Biosciences, Catalent, Synaffix, currently involved ADC technologies are mostly site-specific chemical coupling or enzyme-catalyzed site-specific coupling technology to improve the stability and tolerance of ADC, thereby providing a better therapeutic window
.
Currently, there are only three ADC drugs approved for marketing in China, namely Roche’s HER2 ADC breast cancer drug T-DM1, Takeda’s CD30 ADC drug vebutuximab, and Rongchang Biologic’s HER2 ADC drug vedixituzumab
Coincidentally, yesterday, Daiichi Sankyo and AstraZeneca announced the jointly developed second-line HER2-targeting antibody conjugate DS-8201 for the second-line treatment of HER2-positive unresectable and/or metastatic breast cancer Phase 3 H2H trial DESTINY-Breast03 (NCT03529110 ) Top line data
.
The results of the study showed that DS-8201vs T-DM1 significantly improved PFS, and the trial achieved superiority
In summary, with the advancement of ADC research and development, ADC-related transactions are bound to usher in new opportunities
.
The update and iteration of new targets and new technologies jointly promote ADC to achieve greater clinical value and commercial value, and the follow-up progress of ADC drugs is also worth looking forward to
